| Expression pattern: |
UP |
| Associated gene: |
CD47, Argonaute-2 (Ago2) |
| Associated microRNA: |
miR-152-3p |
| Biological function: |
promotes bortezomib resistance, promotes proliferation, inhibits apoptosis in multiple myeloma cells |
| Molecular mechanism: |
ceRNA sponging of miR-152-3p leading to increased CD47 expression |
| Biological pathway or process: |
chemoresistance (promotes); proliferation (promotes); apoptosis (inhibits); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; Clinical Sample Validation; Survival Analysis; CCK8; Colony Formation Assay; Annexin V/PI Flow Cytometry; Western Blot; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); Transfection; Bioinformatics Analysis |
| Clinical significance: |
high expression of circRERE was associated with disease stage and chemoresistance; circRERE upregulation could predict poor prognosis of MM patients |
| Description: |
circRERE is up-regulated in bortezomib-resistant multiple myeloma serum and resistant MM cell lines. It promotes BTZ resistance by acting as a ceRNA sponge for miR-152-3p, thereby relieving repression of CD47, enhancing proliferation and reducing apoptosis; higher circRERE levels correlate with chemoresistance and poorer survival. |
| Confidence score: |
0.8287 |